Still Waiting for the Golden Goose... The Golden Goose:

New Post Public Reply Private Reply Replies (0) Message Board
jpetroinc
Still Waiting for the Golden Goose...

The Golden Goose: Preparing PhenoGuard to Lay the Next Golden Egg
Tues., November 12th, 2013 at 10:03 AM

http://www.thechairmansblog.com/amarantus-bio...yL6jC.dpuf

Neurotrophic factors don’t come around every day. Since the first neurotrophic factor (NGF) was discovered in 1950’s by Rita Levi-Montalcini’s group, the feat of discovery has been repeated well under 30 times. Moreover, never has the discovery process been meticulously engineered to yield a molecule with an activity profile to treat a specific indication; except in the case of MANF which was discovered for the treatment of Parkinson’s disease. The fact that MANF has been shown to be effective in treating various models of disease in animals gives us a glimpse of what might be possible if we discover more growth factors with the purpose of treating other neurodegenerative diseases.

When I was leading the Neurotrophic Factors Group at the National Institutes of Health in the 1990s, I had a very keen interest in astrocytes because they dramatically outnumber neurons in terms of number of cells and morphological complexity.

After years of research, our team was the first to demonstrate that astrocytes from one region of the brain (substantia nigra) secreted molecules that protected neurons from that region of the brain (dopaminergic neurons of the substantia nigra) better than astrocytes from any other brain region could. Shortly after we published our findings, another group published an almost identical set of results, giving us the confidence that we were on the right track.

From there, another important issue needed to be resolved: In order to use astrocytes as a tool for discovering the neurotrophic factors responsible for the protection we were seeing, we needed a stable source of astrocytes capable of being used in a systematic screening process over and over again. It was here that I reached into some of my early research experience to engineer some proprietary methods to immortalize the astrocytes we were using to generate the initial results in order to turn them into stable cell lines that could be used for neurotrophic factor discovery. We achieved success at 2am one Thursday morning in 1997, the first PhenoGuard cell line (VMCL1) was created, and from there on in my mind it became only a matter of time until multiple neurotrophic factors would be discovered from this methodology. We began using our cell culture to assist companies in drug discovery efforts in 1998, helping Teva Pharmaceuticals in their screening process and ultimately advising them to select Rasagiline from a group of candidates they were evaluating. Rasagiline was approved in 2006, and was the first proof of principle that our cell culture had validity in identifying approvable drug candidates.

Fast forward to 2002, my team discovered and patented MANF using the same cell culture alongside our PhenoGuard cell lines as the biological approach to our neurotrophic discovery program, with MANF ultimately having the signature of protecting dopaminergic neurons that we saw in the cell lines. Shortly after MANF’s sequence was first made public at Dr. Levi-Montalcini’s neurotrophic factors conference in Modena, Italy, the homologue of MANF, CDNF (previously known as MANF2) was discovered by a group at the University of Helsinki using a bioinformatics approach based on MANF. Taken together, MANF and CDNF represent a new neurotrophic factor family discovered as a result of our PhenoGuard discovery platform.

With proof of principle established in various animal models for MANF, the addition of a seasoned drug development organization to the Amarantus team, and the recent move of the Company to a facility where we will have access to all the necessary equipment to restart the PhenoGuard program, I am eager to set about the business of discovering a new neurotrophic factor family. The scientific methods have advanced tremendously in the last decade, which gives me confidence that we will be able to achieve results while deploying significantly fewer resources than we did while discovering MANF. Coupled with our partnering business model, we believe we will be able to find the appropriate partner for PhenoGuard to fully exploit the true value of this technology.

Proving that the discovery of MANF was not serendipitous would represent a massive scientific achievement for the Company in this era of outsourced drug discovery in the pharmaceutical industry. We expect to be in a position to start collaborating on this project in early 2014 having expanded our PhenoGuard cell line library to 88 cell lines from four distinct brain regions associated with Parkinson’s, Alzheimer’s, Clinical Depression and Huntington’s disease.

Science can sometimes be an uncertain endeavor, however with proper parameters established, it has the potential to yield groundbreaking advances in medicine. We believe PhenoGuard could be one such engine in the emerging era of neurotrophic factor development.

Warmest Regards,

John W. Commissiong, PhD

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 261

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 305

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 210

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 156

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 460

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 272

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 278

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 220

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 256

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 213

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading

Top 5 Most Recently Viewed Articles

Clene Inc. Set to Showcase Innovations at Key Conference

Updated Category News Views 149

Clene Inc. Ready for Emerging Growth Conference Presentation Clene Inc. (NASDAQ: CLNN), a pioneering clinical-stage biopharmaceutical company, is set to present at the Emerging Growth Conference. This upcoming event marks a significant opportunity for Clene to showcase its groundbreaking approach in the realm of mitochondrial health and neuroprotection, particularly with...

Continue Reading
Corbion Launches €10 Million Share Buyback Initiative for Employees

Updated Category News Views 223

Corbion Introduces a New Share Buyback Program Corbion N.V. is thrilled to announce its latest initiative, a share buyback program, set to repurchase ordinary shares for a total maximum value of €10 million and up to 580,383 shares. This strategic move underscores the company's commitment to supporting its employees while reinforcing its economic stability. Program...

Continue Reading
SPRY Therapeutics Celebrates Recognition with G2 Fall 2024 Badges

Updated Category News Views 251

SPRY Therapeutics achieved a significant milestone back in Fall 2024, snagging 12 badges from the G2 Reports for its groundbreaking AI-powered electronic medical record (EMR) system. This isn't just another award; it speaks volumes about their positioning across crucial areas like Physical Therapy, Medical Billing, Electronic Health Records (EHR), Patient Scheduling, and...

Continue Reading
Flanigan's Enterprises Showcases Impressive Earnings Growth

Updated Category News Views 137

Flanigan's Enterprises Reports Earnings Growth Flanigan's Enterprises, Inc., (NYSE AMERICAN: BDL) is recognized for its distinguished restaurants and retail liquor stores. The company recently showcased its financial performance for the latest 13-week and 39-week periods, and the results demonstrate substantial growth. Overview of Financial Performance For the 13 weeks...

Continue Reading
Continued Investigation into iRhythm Technologies' Management by KSF

Updated Category News Views 174

Ongoing Investigation of iRhythm Technologies New York based Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is actively investigating iRhythm Technologies, Inc. (NASDAQ: IRTC). The firm is probing potential breaches of fiduciary duty by the company’s directors and officers. The focus is on their responsibilities to shareholders in...

Continue Reading